Glaukos Co. (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Glaukos Co. (NYSE:GKOS) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $112.27.

GKOS has been the topic of several analyst reports. Truist Financial reaffirmed a “buy” rating and set a $125.00 price target (up previously from $120.00) on shares of Glaukos in a research report on Thursday, May 2nd. Jefferies Financial Group upgraded Glaukos from a “hold” rating to a “buy” rating and increased their price target for the stock from $84.00 to $125.00 in a report on Monday, May 6th. Stifel Nicolaus lifted their price target on shares of Glaukos from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, June 5th. JPMorgan Chase & Co. boosted their price target on shares of Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Finally, BTIG Research increased their price objective on shares of Glaukos from $107.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd.

Insider Activity

In other news, CFO Alex R. Thurman sold 434 shares of Glaukos stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $95.33, for a total transaction of $41,373.22. Following the sale, the chief financial officer now owns 54,166 shares in the company, valued at $5,163,644.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Alex R. Thurman sold 1,372 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $100.54, for a total transaction of $137,940.88. Following the completion of the sale, the chief financial officer now owns 52,532 shares in the company, valued at $5,281,567.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Alex R. Thurman sold 434 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $95.33, for a total value of $41,373.22. Following the transaction, the chief financial officer now directly owns 54,166 shares in the company, valued at approximately $5,163,644.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 81,001 shares of company stock worth $8,344,878. Corporate insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Glaukos

Several institutional investors have recently bought and sold shares of GKOS. Xponance Inc. grew its holdings in Glaukos by 4.1% during the fourth quarter. Xponance Inc. now owns 2,879 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 113 shares during the period. Valeo Financial Advisors LLC lifted its stake in shares of Glaukos by 1.7% in the first quarter. Valeo Financial Advisors LLC now owns 8,932 shares of the medical instruments supplier’s stock valued at $902,000 after purchasing an additional 150 shares during the period. Corient Private Wealth LLC boosted its holdings in Glaukos by 0.7% during the fourth quarter. Corient Private Wealth LLC now owns 24,775 shares of the medical instruments supplier’s stock worth $1,969,000 after buying an additional 163 shares in the last quarter. Quadrant Capital Group LLC grew its position in Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock worth $74,000 after buying an additional 329 shares during the period. Finally, Mariner LLC increased its holdings in Glaukos by 7.1% in the third quarter. Mariner LLC now owns 6,218 shares of the medical instruments supplier’s stock valued at $468,000 after buying an additional 411 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Stock Up 1.3 %

GKOS opened at $118.96 on Wednesday. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78. Glaukos has a twelve month low of $59.22 and a twelve month high of $121.04. The company has a market cap of $5.99 billion, a PE ratio of -41.31 and a beta of 1.06. The company has a 50-day moving average price of $109.95 and a 200 day moving average price of $96.91.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The firm had revenue of $85.60 million during the quarter, compared to analyst estimates of $79.60 million. During the same period in the prior year, the firm earned ($0.59) earnings per share. The business’s revenue was up 15.8% on a year-over-year basis. Sell-side analysts expect that Glaukos will post -2.24 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.